Pembrolizumab for advanced cervical cancer: safety and efficacy

Autor:	Giovanni Scambia, Elena Giudice, Maria Grazia Distefano, Francesca De Felice, Anna Fagotti, Claudia Marchetti, G. Bolomini
Rok vydání:	2020
Předmět:	0301 basic medicine cervical cancer immunotherapy metastatic pembrolizumab recurrent medicine.medical_treatment Immune checkpoint inhibitors Uterine Cervical Neoplasms Pembrolizumab Antibodies Monoclonal Humanized B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Programmed cell death 1 medicine Humans Pharmacology (medical) In patient Receptor Immune Checkpoint Inhibitors Cervical cancer biology business.industry Immunotherapy medicine.disease Settore MED/40 - GINECOLOGIA E OSTETRICIA 030104 developmental biology Oncology 030220 oncology & carcinogenesis Disease Progression biology.protein Cancer research Female business
Zdroj:	Expert Review of Anticancer Therapy. 21:221-228
ISSN:	1744-8328 1473-7140
DOI:	10.1080/14737140.2021.1850279
Popis:	Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by the FDA in patients with recu...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a244fb28476f8cbafa7bc7ff906a54c7 https://doi.org/10.1080/14737140.2021.1850279 Zobrazit plný text záznamu